1067657-85-5

Upstream product

• 104-86-9 4-chlorobenzylamine 
• 540523-98-6 3-(4-chloro-2-nitro-phenyl)-2-oxo-propionic acid ethyl ester 
• 89-59-8 4-chloro-2-nitrotoluene 
• 36635-66-2 α-tosylbenzyl isocyanide 

Downstream Products

• 1067657-84-4 6-chloro-3-(1-(4-chlorobenzyl)-4-phenyl-1H-imidazol-5-yl)-1H-indole-2-carboxylic acid 
• 1067655-24-6 {6-chloro-3-[3-(4-chloro-benzyl)-5-phenyl-3H-imidazol-4-yl]-1H-indol-2-yl}-methanol 
• 1067655-32-6 6-chloro-3-[2-chloro-3-(4-chlorobenzyl)-5-phenyl-3H-imidazol-4-yl]-1H-indole-2-carboxylic acid ethyl ester 
• 1067653-58-0 6-chloro-3-[3-(4-chlorobenzyl)-5-phenyl-3H-imidazol-4-yl]-1H-indole-2-carboxylic acid (2-morpholin-4-ylethyl)amide 
• 1067655-26-8 {6-chloro-3-[3-(4-chloro-benzyl)-5-phenyl-3H-imidazol-4-yl]-1H-indol-2-ylmethyl}-(2-morpholin-4-yl-ethyl)-amine 
• 1067657-22-0 6-chloro-3-[3-(4-chloro-benzyl)-5-phenyl-3H-imidazol-4-yl]-2-(4,5-dihydrooxazol-2-yl)-1H-indole 

Relevant academic research and scientific papers

NOVEL P53-MDM2/P53-MDM4 ANTAGONISTS TO TREAT PROLIFERATIVE DISEASE

High-resolution structural information delineates key interactions between MDM2 or MDM4 and heterocyclic compounds that bind to these proteins. These compounds are potent agonists of the p53-MDM2/p53-MDM4 complex.

Substituted Heterocycles as Therapeutic agents for treating cancer

MDM2 and MDM4 proteins prevent apoptosis of cancer cells by negatively regulating the transcription factor p53. Compounds according to Formula I are selective antagonists of MDM2 and MDM4 proteins, disrupting the p53/MDM2 and p53/MDM4 complex. These compo

3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.